Agneta Nordberg1. 1. Karolinska Institutet, Division of Molecular Neuropharmacology, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden. agneta.k.nordberg@ki.se
Abstract
PURPOSE OF REVIEW: This paper reviews the progress in developing amyloid imaging ligands to be used to measure amyloid in vivo in the brain of patients with Alzheimer's disease. RECENT FINDINGS: Four radioligands, [18F] 1,1-dicyano-2-[6-(dimethylamino)-2-naphtalenyl] propene or 18F-FDDNP, N-methyl [11C] 2-(4'-methylaminophenyl)-6-hydroxy-benzothiasole or 11C-PIB, 4-N-methylamino-4'-hydroxystilbene [11C] or SB13 and 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole or 11C-BF-227, have so far been studied in Alzheimer's disease patients and age-matched healthy controls by PET. A robust difference was observed between PIB retention in mild patients and controls. A 2-year follow-up study in mild patients showed a stable level of PIB retention and a decrease in cerebral glucose metabolism and cognition. 18F-FDDNP showed less difference between Alzheimer's disease patients and controls compared with PIB. Both ligands have detected increases in amyloid in the brain of patients with mild cognitive impairment. SUMMARY: The new PET amyloid imaging technique is a breakthrough in understanding the pathophysiological mechanisms and time course in amyloid deposits in the brain. The technique will enable early detection of Alzheimer's disease. PET amyloid imaging should be used in the evaluation of new antiamyloid therapies.
PURPOSE OF REVIEW: This paper reviews the progress in developing amyloid imaging ligands to be used to measure amyloid in vivo in the brain of patients with Alzheimer's disease. RECENT FINDINGS: Four radioligands, [18F] 1,1-dicyano-2-[6-(dimethylamino)-2-naphtalenyl] propene or 18F-FDDNP, N-methyl [11C] 2-(4'-methylaminophenyl)-6-hydroxy-benzothiasole or 11C-PIB, 4-N-methylamino-4'-hydroxystilbene [11C] or SB13 and 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole or 11C-BF-227, have so far been studied in Alzheimer's diseasepatients and age-matched healthy controls by PET. A robust difference was observed between PIB retention in mild patients and controls. A 2-year follow-up study in mild patients showed a stable level of PIB retention and a decrease in cerebral glucose metabolism and cognition. 18F-FDDNP showed less difference between Alzheimer's diseasepatients and controls compared with PIB. Both ligands have detected increases in amyloid in the brain of patients with mild cognitive impairment. SUMMARY: The new PET amyloid imaging technique is a breakthrough in understanding the pathophysiological mechanisms and time course in amyloid deposits in the brain. The technique will enable early detection of Alzheimer's disease. PET amyloid imaging should be used in the evaluation of new antiamyloid therapies.
Authors: Jeyanthy Sutharsan; Marianna Dakanali; Christina C Capule; Mark A Haidekker; Jerry Yang; Emmanuel A Theodorakis Journal: ChemMedChem Date: 2010-01 Impact factor: 3.466
Authors: Willy M Chang; Marianna Dakanali; Christina C Capule; Christina J Sigurdson; Jerry Yang; Emmanuel A Theodorakis Journal: ACS Chem Neurosci Date: 2011-05-18 Impact factor: 4.418
Authors: Mehul A Trivedi; Christopher M Murphy; Celine Goetz; Raj C Shah; John D E Gabrieli; Susan Whitfield-Gabrieli; David A Turner; Glenn T Stebbins Journal: Dement Geriatr Cogn Disord Date: 2008-07-28 Impact factor: 2.959
Authors: M N Rajah; S Bastianetto; K Bromley-Brits; R Cools; M D'Esposito; C L Grady; J Poirier; R Quirion; N Raz; E Rogaeva; W Song; J Pruessner Journal: Ageing Res Rev Date: 2009-04 Impact factor: 10.895
Authors: Claudia Kuntner; Adam L Kesner; Martin Bauer; Robert Kremslehner; Thomas Wanek; Markus Mandler; Rudolf Karch; Johann Stanek; Tanja Wolf; Markus Müller; Oliver Langer Journal: Mol Imaging Biol Date: 2009-02-13 Impact factor: 3.488